Physician profile
Jason Kovacevic
NPI 1275952061
$6,981.27
in general payments reported to CMS, 2019-2025
11 companies · $5,266 in 2025
The $5,266 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $1,021 · 2023: $296 · 2024: $103 · 2025: $5,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,600 · Food and Beverage: $1,550 · Travel and Lodging: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,599.99 |
| Food and Beverage | $1,549.64 |
| Travel and Lodging | $1,515.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,544.34 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $831.74 | 2021-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $811.90 | 2021-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $317.58 | 2022-2023 | Fasenra |
| Olympus America INC. | $150.00 | 2022 | |
| Merck Sharp & Dohme LLC | $86.40 | 2024 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.62 | 2021-2022 | |
| Harmony Biosciences LLC | $68.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.88 | 2022 | |
| Genzyme Corporation | $31.84 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kovacevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.